Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifepristone as Adjunctive Therapy in Alzheimer's Disease
NCT00105105Phase 2Terminated
- Sponsor
- Corcept Therapeutics
- Start
- Apr 2003
- Primary completion
- Nov 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Mifepristone Arm with Placebo Arm (2 arms). Primary endpoint: Effects on Cognition at 16 weeks. Started Apr 2003; status: terminated.
02
Drugs
mifepristone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00105105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00105105.